dicembre 2022 - Business NewsWire

Rising Disease Prevalence To Drive Professional Acne Treatment Market to $13,124.5 Million by 2030

From $6,298.9 million in 2020, the global professional acne treatment market value is predicted to reach $13,124.5 million by 2030, at a 7.6% CAGR between 2020 and 2030.

The market is being driven by the following factors:

Rising Prevalence of Acne: Almost 90% of the people on earth, especially young adults and adolescents, get acne at some point in their lives. Moreover, the Global Burden of Disease study estimates the 2019 incidence of this common dermatological issue at 50 million cases in the U.S. alone.
Adoption of Sedentary Lifestyle: This is another key driver for the professional acne treatment market as being less physically active leads to a rise in weight and the levels of lipids in the body. This, in turn, upsets the hormone concentration, which results in an array of skin diseases, including hormonal acne.

The coming years will be characterized by the faster growth of the inflammatory bifurcation in the professional acne treatment market, on the basis of acne type. This kind of acne is considered severer than the non-inflammatory type, and it is often painful. Additionally, inflammatory acne cannot be cured by most of the drugs available over the counter (OTC), which is why a professional’s intervention is preferred.

Nowadays, the increasing focus of pharmaceutical companies on introducing new products is becoming a prominent trend in the professional acne treatment market. For example, in August 2020, Cassiopea SpA received the U.S. Food and Drug Administration (FDA) approval for Winlevi, an acne treatment cream derived from clascoterone. This cream has been developed for treating acne in patients aged 12 years and above. Similarly, in February 2021, VYNE Therapeutics Inc. received the FDA approval for its AMZEEQ (minocycline) topical foam. This foam is designed to treat inflammatory lesions caused by non-nodular moderate-to-severe acne in children aged nine years or more and adults.

The acne type segment of the professional acne treatment market is bifurcated into inflammatory and non-inflammatory. Of these, the inflammatory category generated the higher revenue in 2020 due to the surging need for an effective treatment for inflammatory acne, as it is usually painful. A large number of pharmaceutical companies are offering branded and generic drugs for inflammatory acne, as the commonly available benzoyl-peroxide and salicylic-acid-based over-the-counter (OTC) products are not completely effective on it.

High Burden of Chronic Diseases To Drive Active Pharmaceutical Ingredient Demand

The International Agency for Research on Cancer (IARC) states that 10 million cancer deaths and 19.3 million new cancer cases were recorded in 2020. As per the IARC, 1 in 5 people around the world develops cancer during their lifetime. Further, the World Health Organization (WHO) estimates that approximately 17.9 million human lives were lost due to cardiovascular diseases (CVDs) in 2019. Additionally, the WHO states that over 3 million people each year die of chronic obstructive pulmonary disease (COPD), accounting for over 6% of the global deaths.

The rising incidence of such chronic diseases is projected to propel the active pharmaceutical ingredient (API) market at a CAGR of 6.9% during the forecast period (2021–2030). Additionally, P&S Intelligence states that the booming geriatric population will help the market revenue surge from $184,311.2 million in 2020 to $357,005.7 million by 2030. According to the United Nations Department of Economic and Social Affairs (UNDESA), the number of people aged 65 years or above will increase from 727 million in 2020 to around 1.5 billion by 2050.

Nowadays, captive and merchant manufacturers are producing generic and innovative APIs, which are available through online and offline channels. In contemporary times, innovative APIs are being used in higher quantities due to the mounting focus of pharmaceutical companies on developing new and more-effective medicines. In the coming years, captive manufacturers will emerge as the larger producer of APIs due to the stringent quality control and drug safety guidelines the pharma sector is subject to and the higher budgets captive companies possess for research and development (R&D).

The therapeutic application segment of the active pharmaceutical ingredient market is categorized into CVDs, communicable diseases, diabetes, oncology, pain management, respiratory diseases, and others. Among these, the oncology category held the largest market share in 2020, primarily on account of the high burden of cancer and extensive demand for highly potent APIs (HPAPIs) for cancer treatment. The WHO estimates that cancer caused approximately 10 million fatalities around the world in 2020. It also states that 1.93 million, 2.21 million, and 2.26 million people were diagnosed with colon and rectum, lung, and breast cancer, respectively, in 2020.

In recent years, pharma firms, such as Eli Lilly and Company, Mallinckrodt plc, Merck & Co. Inc., Lupin Limited, Johnson & Johnson, STADA Arzneimittel AG, AbbVie Inc., MSN Laboratories Pvt. Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca plc, and Sanofi, have been introducing new products, entering into collaborations and partnerships, and expanding their production capacities, to offer APIs to a greater number of customers. For example, in July 2021, Pfizer Inc. collaborated with Arvinas Inc. to develop and sell PROTAC estrogen receptor protein degrader ARV-471.

Globally, the North American active pharmaceutical ingredient market is expected to generate the highest revenue during the forecast period, owing to the rising burden of chronic diseases, mounting demand for specialty drugs and biologics, surging government focus on generic drugs, increasing technological advancements, and soaring number of R&D initiatives in the pharmaceutical industry. Moreover, the growing public awareness regarding numerous lifestyle-related diseases, such as diabetes, is expected to drive the API demand in the region.

How Wearable Electrodes Can Help in EKG Monitoring?

The use of wearables for health and wellness monitoring is quickly growing. In the years gone by, wearable technology has become popular. For several years, wearables have offered elementary features like step count. Though, over time these features have grown to offer more cutting-edge physical measurements like heart electrical activity.

ECG monitoring is becoming one of the most striking health features of smartwatches. With CVD being one of the foremost reasons of worldwide deaths, the usage of smartwatches to monitor patients remotely could improve the care of heart injury.’

Dry Electrode challenges in EKG development

For detecting EKG, electrodes are needed on a device. This detection interface is a critical constituent in allowing the correctness that will be compulsory, but it can be difficult to implement, particularly with the use of dry electrodes.

When working at electrode stage of the cycle of EKG development, there are numerous challenges like physical design, electrode material choice, the characteristics of the skin location, aesthetic requirements as well as meeting the complete performance necessities of end device. On system level, some of these challenges can be lessened through intelligent signal conditioning algorithms, though, taking a holistic method and tackling all parts of the signal chain will guarantee a world class customer experience.

Some issues faced with electrodes are:

Electrode Skin Interface

Skin is the largest body organ, and is fabricated from numerous components. The epidermis, has a comparatively high impedance opposing the transfer of the EKG signal. In a wet electrode, this is lessened by the conductive electrolyte; in dry electrodes, sweat executes this function. The electrode alters this charge in sweat into electric charge that can be used by the device hardware.

Dry Electrode Mechanical Design

The EKG dry electrodes performance can be impacted by position, size, and surface finish. For a given material, dissimilar sizes and the body position can affect the contact with the skin and the subsequent signal can vary suggestively in quality. The finish of the surface can alter the contact mechanisms, and some coverings can even further obstruct the movement of the EKG signal.

A good amount of data can be collected with the help of wearable sensors for monitoring and recording real-time info about patients’ health. So, it is vital for managing and overcoming these issues to let better-quality sensor performance.

With the increase in technology in the medical industry, medical electrodes are high in demand worldwide.

Browse Full Report Medical Electrodes Market Key Drivers

Increasing Incidence of Chronic Diseases Driving Advancement of Chronic Pain Treatment Market

From $77.8 billion in 2019, the global chronic pain treatment market is predicted to reach a value of $151.7 billion by 2030. According to the estimates of P&S Intelligence, a market research company based in India, the market would advance at a CAGR of 6.5% between 2020 and 2030. The market is being driven by the rising government support for various chronic pain treatment procedures, the surging geriatric population, and the growing incidence of chronic health problems around the world.

The governments of many countries across the world are launching initiatives for raising public awareness about advanced pain treatment items and providing funding for the same, thereby fueling the expansion of the industry. For example, the Developing Countries Project of the International Association for the Study of Pain (IASP) was implemented between January and March 2018 for advancing pain treatment practice and education in the emerging economies with the help of grants.

As per the 2019 World Population Ageing report, there were as many as 703 million persons in the age bracket- 65 years or above all over the world in that year. The report said that over half of the geriatric people in the world in 2019 suffered from multiple chronic health ailments. The rising incidence of chronic diseases is another important factor driving the progress of the market. Orthopedic diseases, neurological disorders, and cancer cause long-term pain in patients.

As per the WHO, the low- and middle-income countries witness the deaths of nearly 70% of the total worldwide cancer deaths. Furthermore, migraine, lower back pain, joint pain, and neck pain generate huge requirement for pain treatment services such as psychological therapies, neuroablation, and physiotherapy throughout the world. Many drugs produced by the players operating in the industry for the treatment of various chronic diseases are currently under clinical trials.

Depending on product, the chronic pain treatment market is classified into devices and drugs. Between these, the drugs category recorded higher growth in the market in the past years. Globally, the market registered the highest growth in North America during the last few years and this trend will continue in the upcoming years as well. This would be because of the soaring population of geriatric people in the regional countries.

Hence, it can be safely concluded that the market will demonstrate huge growth all over the world in the forthcoming years, primarily because of the rising incidence of chronic diseases and the surging geriatric population in several countries around the world.